Are SGLT2 inhibitors a targeted treatment for diabetic kidney disease?
Author:
Publisher
Elsevier BV
Subject
Nephrology
Reference9 articles.
1. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials;Zelniker;Lancet,2019
2. Perkovic V, Jardine MJ, Neal B, et al., for the CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy [e-pub ahead of print]. N Engl J Med. https://doi.org/10.1056/NEJMoa1811744. Accessed April 14, 2019.
3. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus
4. Sodium-glucose cotransporter 2 inhibition and diabetic kidney disease;Alicic;Diabetes,2019
5. Kidokoro K, Cherney DZI, Bozovic A, et al. Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging [e-pub ahead of print]. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.118.037418. Accessed February 18, 2019.
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. SGLT2i treatment during AKI and its association with major adverse kidney events;Frontiers in Pharmacology;2024-06-12
2. Metformin and Canagliflozin Are Equally Renoprotective in Diabetic Kidney Disease but Have No Synergistic Effect;International Journal of Molecular Sciences;2023-05-20
3. Machine-learning-based Web system for the prediction of chronic kidney disease progression and mortality;PLOS Digital Health;2023-01-18
4. Icariin Attenuation of Diabetic Kidney Disease Through Inhibition of Endoplasmic Reticulum Stress via G Protein-Coupled Estrogen Receptors;Journal of Biomedical Nanotechnology;2022-02-01
5. Management of the Failing Kidney Transplant: Challenges and Solutions;Experimental and Clinical Transplantation;2021-10-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3